Blood biomarkers are transforming research and clinical care for dementia, Alzheimer’s, and other neurodegenerative diseases. Led by Nicholas Ashton, Ph.D., our upcoming webinar will explore biomarkers’ evolution, from global proteomics to disease-specific markers such as p-Tau 217, GFAP, and amyloid-beta. The session will focus on the utility of plasma p-Tau 217, and will look to future possibilities — including remote testing and emerging markers — to further highlight biomarkers’ role in improving dementia diagnosis and treatment. https://bit.ly/3RbEFUB #Neurodegeneration #Research #Biomarkers
Quanterix’s Post
More Relevant Posts
-
Today is World Alzheimer’s Day, and a time to reflect on the impact this disease has worldwide. At Olink, we are dedicated to advancing research that uncovers the cellular mechanisms behind Alzheimer’s disease and supports early detection studies. Our PEA technology continues to contribute to many studies exploring the biology of neurological diseases worldwide. We deeply appreciate the dedication of researchers, healthcare professionals, caregivers, and the many families and friends who are affected by this challenging disease. For an insight into the latest research into AD, please watch a webinar presented by Dr. Margaret Doyle from the University of Vermont, "Circulating inflammatory biomarkers associated with cognitive function and dementia": https://hubs.la/Q02QBPJF0 To see more examples of proteomics in AD research, visit our website: https://hubs.la/Q02QBNWb0
-
Post-doctoral researcher - Alzheimer Centrum Limburg - Mental Health and Neuroscience Research Institute - Maastricht University
🧠 New publication! 🧠 Our paper "CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease" is now published in Alzheimer's & Dementia! 📢 Results showed that: 💡 Neurogranin, neurofilament light, and hippocampal volume were associated with distinct cerebrospinal fluid proteomic profiles, reflecting different neurodegenerative processes in AD. 💡 Neurogranin and neurofilament light were associated with neuroplasticity, although in opposite directions. 🚨 Different neurodegeneration markers should not be equated and may differentially complement disease staging beyond amyloid and tau. 🚨 Neurogranin might not be an optimal neurodegeneration marker, as it relates more closely to tau. The full article can be read here 👇 : https://lnkd.in/eZUqTTxX A great thanks to my team and co-authors! Stephanie Vos Pieter Jelle Visser
-
🔬 Innovating Alzheimer's Research: A Potential Biomarker Identified In the ongoing quest to understand and combat Alzheimer's disease, a groundbreaking study published in NeuroMarkers has identified BCL2 interacting protein 3 as a potential biomarker for the condition. This observational study sheds light on the early signs of Alzheimer's, focusing on mitochondrial dysfunction as a key indicator. The study reveals that the expression levels of BCL2 interacting protein 3 are positively correlated with Mini-Mental State Examination scores, suggesting that lower levels of this protein are associated with a higher degree of dementia. This finding could revolutionize early detection and intervention strategies for Alzheimer's disease. The research delves into the roles of mitophagy receptors BCL2 interacting protein 3 and BCL2 interacting protein 3 like (NIX), which are regulated by protein phosphatase targeting COQ7 (PPTC7). These proteins play a crucial role in controlling the quantity of mitochondria within cells, and their decreased expression under Alzheimer's disease conditions is a significant discovery. For professionals in the fields of neuroscience, gerontology, and healthcare, understanding these biomarkers is crucial for advancing diagnostics and treatment. The full article is a must-read for anyone interested in the latest scientific developments in Alzheimer's research. 📚 Read the full article here: [BCL2 interacting protein 3 as a potential biomarker for Alzheimer’s disease: an observational study] https://lnkd.in/g_34fAbY About the journal: NeuroMarkers is an international, peer-reviewed, open access journal that aims to publish the high-quality, innovative research that addresses biomarker investigation from all Nervous System Diseases. The journal studies the identification and validation of biomarkers in neurological diseases to aid diagnosis, prognosis, response to therapy, and elucidating mechanisms. Also aims to reduce the incidence of misdiagnoses and inappropriate treatment. #AlzheimersDisease #Biomarker #Neuroscience #HealthcareInnovation #MitochondrialHealth #LinkedInLearning
-
Business Development Manager at Quanterix | Ultrasensitive Biomarkers Specialist | Client Relation Expertise | RNA Targeting Leader
Discover the future of dementia diagnosis. Quanterix’s upcoming webinar with Nicholas Ashton, Ph.D., will dive into blood biomarkers like p-Tau 217, GFAP, and amyloid-beta. Register now to explore emerging markers: #Neurodegeneration #Research #Biomarkers
-
Life Science Product Leader │ Global Product Management & Marketing │ Cross-functional Team Leadership │ Build and commercialize products that empower research and improve health care
Discover the future of dementia diagnosis. Quanterix’s upcoming webinar with Nicholas Ashton, Ph.D., will dive into blood biomarkers like p-Tau 217, GFAP, and amyloid-beta. Register now to explore emerging markers: #Neurodegeneration #Research #Biomarkers
-
Discover the future of dementia diagnosis. Quanterix’s upcoming webinar with Nicholas Ashton, Ph.D., will dive into blood biomarkers like p-Tau 217, GFAP, and amyloid-beta. Register now to explore emerging markers: #Neurodegeneration #Research #Biomarkers
-
🌟 In-silico Studies & Neuroprotective Insights on Microencapsulated Celecoxib in Alzheimer's Research 🌟 An innovative study published in Volume 31, Issue 4, 2025 explores the neuroprotective potential of microencapsulated celecoxib (MCXB) for Alzheimer's Disease (AD). Using advanced molecular docking and in-vivo experiments, the research reveals how MCXB enhances bioavailability and combats neurodegeneration. 📚Key findings: •Significant improvements in oxidative stress markers and neurochemical biomarkers. •Dose-dependent neuroprotection, fostering neuronal regeneration and reducing damage. •Histopathological evidence of improved brain cell health, especially in the hippocampus. This study emphasizes the therapeutic promise of MCXB in AD treatment, marking a crucial step in neurodegenerative research. 📢 Call for Papers Submit your innovative studies on neuroprotective agents, Alzheimer’s Disease, and drug delivery systems. Share your new research with us and contribute to the future of neurodegenerative disorder treatments. 🔗 Read the full article here: https://bit.ly/3ZdEFqC #AlzheimersResearch #Neuroprotection #Celecoxib #Microencapsulation #BiomedicalResearch #Neurodegeneration #CallForPapers #InnovationInScience #EditorChoice
-
-
Discover the future of dementia diagnosis. Quanterix’s upcoming webinar with Nicholas Ashton, Ph.D., will dive into blood biomarkers like p-Tau 217, GFAP, and amyloid-beta. Register now to explore emerging markers: #Neurodegeneration #Research #Biomarkers
-
Discover the future of dementia diagnosis. Quanterix’s upcoming webinar with Nicholas Ashton, Ph.D., will dive into blood biomarkers like p-Tau 217, GFAP, and amyloid-beta. Register now to explore emerging markers: #Neurodegeneration #Research #Biomarkers
-
Discover the future of dementia diagnosis. Quanterix’s upcoming webinar with Nicholas Ashton, Ph.D., will dive into blood biomarkers like p-Tau 217, GFAP, and amyloid-beta. Register now to explore emerging markers: #Neurodegeneration #Research #Biomarkers
